Double beat from their earnings this morning and some attractive growth numbers. YoY:
Ozempic Revenue: DKK 34.6B | YoY: +39%
Wegovy Revenue: DKK 12.9B | YoY: +88%
Rybelsus Revenue: DKK 9.8B | YoY: +27%
Rare Disease Revenue: DKK 8.7B | YoY: +2%
North America Revenue: DKK 48.5B | YoY: +36%
International Revenue: DKK 32.5B | YoY: +19%
Price is up +3.5% in the PM now and aligns very nicely with our potential Wave B bounce up to $114 next.
Growth is still expected to be between 16% - 24%, so a lot of indications are showing that $NVO is back on track
Martin Charles Christiansen
2025-02-05 20:57:48 +0000 UTCSofiane
2025-02-05 11:51:36 +0000 UTC